BR0215935A - Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica - Google Patents

Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica

Info

Publication number
BR0215935A
BR0215935A BR0215935-0A BR0215935A BR0215935A BR 0215935 A BR0215935 A BR 0215935A BR 0215935 A BR0215935 A BR 0215935A BR 0215935 A BR0215935 A BR 0215935A
Authority
BR
Brazil
Prior art keywords
treatment
acute leukemia
myelodysplastic syndrome
combination therapy
pharmaceutical combinations
Prior art date
Application number
BR0215935-0A
Other languages
English (en)
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0215935A publication Critical patent/BR0215935A/pt

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"TERAPIA COMBINADA PARA TRATAMENTO DE LEUCEMIA AGUDA E SìNDROME MIELODISPLáSICA". A presente invenção refere-se a métodos de tratamento e combinações farmacêuticas para o tratamento de leucemia aguda tal como leucemia mielógena aguda e síndrome mielodisplásica que são fornecidos os métodos de tratamento e combinações farmacêuticas empregam um conjugado citotóxico anti-CD33 em combinação com pelo menos um composto selecionado dentre o grupo consistindo em uma antraciclina e um análogo de nucleosídeo pirimidina ou purina. Métodos preferidos de tratamento e de combinações farmacêuticas empregam gemtuzumab ozogamicina, daunorrubicina e citarrabina.
BR0215935-0A 2002-11-06 2002-11-06 Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica BR0215935A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
BR0215935A true BR0215935A (pt) 2005-08-09

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215935-0A BR0215935A (pt) 2002-11-06 2002-11-06 Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica

Country Status (10)

Country Link
EP (1) EP1575582A4 (pt)
JP (1) JP2006508119A (pt)
CN (1) CN1720044A (pt)
AU (2) AU2002348178A1 (pt)
BR (1) BR0215935A (pt)
CA (1) CA2504611A1 (pt)
CR (1) CR7804A (pt)
MX (1) MXPA05004711A (pt)
NO (1) NO20052009L (pt)
WO (1) WO2004043461A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
AU2006269481A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
EP4046640A1 (en) * 2007-02-16 2022-08-24 Rotalec IP Holdings LLC Fixed drug ratios of cytarabine to daunorubicin for treatment of hematopoietic cancers and proliferative disorders
EP2649997B1 (en) * 2007-12-10 2019-01-23 Sunesis Pharmaceuticals, Inc. (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome
WO2010024374A1 (ja) 2008-08-29 2010-03-04 学校法人北里研究所 Ｄｎａメチル化阻害剤の薬剤効果検出方法
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
TWI753178B (zh) * 2017-06-22 2022-01-21 法商施維雅藥廠 Mcl-1抑制劑與血液癌症標準療法之組合，其用途及醫藥組合物
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
KR20210121138A (ko) * 2019-01-28 2021-10-07 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 암의 치료를 위한 금속 킬레이터 병용 요법
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
CA3199623A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy
WO2025214401A1 (zh) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 抗体药物偶联物、组合物及其用途和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
EP1309627B1 (en) * 2000-08-08 2009-09-30 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia with naked anti-nca-90 antibody

Also Published As

Publication number Publication date
CA2504611A1 (en) 2004-05-27
AU2010201113A1 (en) 2010-04-15
CR7804A (es) 2008-10-29
CN1720044A (zh) 2006-01-11
JP2006508119A (ja) 2006-03-09
AU2002348178A1 (en) 2004-06-03
NO20052009L (no) 2005-06-27
EP1575582A1 (en) 2005-09-21
WO2004043461A1 (en) 2004-05-27
NO20052009D0 (no) 2005-04-25
MXPA05004711A (es) 2005-08-03
EP1575582A4 (en) 2009-03-11

Similar Documents

Publication Publication Date Title
BR0215935A (pt) Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica
ECSP105178A (es) Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para el tratamiento de cáncer en humanos
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
RS20120201A3 (en) Methods and compositions for hepatitis c virus treatment
WO2004087713A8 (en) Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
LT2001083A (en) Tricyclic inhibitors of poly(adp-ribose) polymerases
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
EP1951729A4 (en) OXYGEN-LINKED PYRIMIDINE DERIVATIVES
MXPA05014082A (es) Acidos biariloximetilarenocarboxilicos.
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
WO2006015357A3 (en) 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
GT200100183A (es) Derivados de quinolina y quinazolina.
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
EP1749830A4 (en) CURCUMOL DERIVATIVES, COMPOSITION COMPRISING THE SAME, AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
BRPI0509927A (pt) composição farmacêutica, uso de uma composição de matéria, e, uso de uma combinação terapeuticamente eficaz de um oligonucleotìdeo anti-sentido de survivina e cloridrato de gemcitabina
TW200633992A (en) Biaryloxymethylarenecarboxylic acids
BRPI0415123A (pt) uso de l-butilftalida e respectiva composição farmacêutica
WO2008087558A3 (en) Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use
EE200200087A (et) Kompositsioon hepatotsellulaarse kartsinoomi raviks
PT981358E (pt) Derivados de dolastatina-15 em combinacao com taxanos
PA8590801A1 (es) Derivados de nucleosido antivirales

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements

Free format text: PARA QUE A SOLICITACAO REQUERIDA NA PETICAO NO 020080037113/RJ DE 12/03/2008 SEJA ATENDIDA, APRESENTE DOCUMENTO DE DECLARACAO DE INCLUSAO DE INVENTORES, NO QUAL DEVEM SE MANIFESTAR TODOS OS INVENTORES CONSTITUIDOS NO PEDIDO, UMA VEZ QUE O DOCUMENTO DE CESSAO APRESENTADO NA REFERENTE PETICAO CORRESPONDE A UMA PRIORIDADE QUE NAO FOI REVINDICADA NA FASE NACIONAL, E AINDA A ALTERACAO NAO PODE SER CONFIRMADA PELO DOCUMENTO DE PUBLICACAO INTERNACIONAL.

B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/44, 31/53, 31/70, 31/445; A61P 35/00

Ipc: A61K 31/44 (2011.01), A61K 31/53 (2011.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law
B08L Application fees: final archiving

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 10A E 11A ANUIDADES.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents)

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08I Application fees: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2256 DE 01/04/2014 POR TER SIDO INDEVIDA.

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 10A, 11A, 12A, 13A, 14A, 15A, 16A, 17A E 18A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.